The levels of other fibrinolytic factors, including tissue-type plasminogen activator (tPA), urokinase-type PA (uPA), and one of its main inhibitors called plasminogen activator inhibitor-1 (PAI-1) and the soluble form of the uPA receptor (suPAR) were found to be altered in COVID-19 patients (10). Here, PLAU is linked to COVID-19.